SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is drawing attention amid volatile pre-earnings trading, with traders weighing expectations for Q3 results and possible guidance against a broader selloff in AI and growth stocks tied to inflation and interest-rate concerns. Bulls point to data-center power demand and deals involving AEP, Google and Oracle, while bears question the stocks valuation and warn of further downside or a sell-the-news reaction.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs prolonged selloff and repeated underperformanceeven as Bitcoin has held up or reboundedare driving discussion. Traders largely blame skepticism about the AI/data-center pivot without signed tenant leases and concerns over finances and management, while some see the decline as overdone and anticipate a rebound if Bitcoin strengthens or a deal emerges.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts withdrawal from its UK data-center deal with Nscale, reportedly because grid power may not be available until the 2030s, has fueled discussion about AI infrastructure delays and the economics of the broader buildout. Traders disagree on the implications: some see a warning sign for AI spending and financing, while others view it as a site-specific power constraint rather than a drop in demand.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor is drawing attention after a steep pullback despite two recent Q3 revenue outlook increases, which the company attributed to royalties from its Vertical Power Delivery technology licensing. Traders are divided between buying the weakness ahead of the earnings report and worrying that the selloff reflects fading momentum, profit-taking, or broader pressure on tech stocks.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

A reported jump in ARKGs ARCT share count is driving attention, with traders debating whether it signals a major ARK buy or reflects a reporting error or routine ETF share creation. Some posts cite a correction and say the increase may not represent a deliberate increase in ARKs conviction.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVies run to fresh highs is drawing attention amid a rotation into defensive healthcare stocks, with traders highlighting breakout momentum while some caution that the shares look overextended. Positive Crohns disease and oncology pipeline updates are also part of the discussion, alongside speculation about AbbVie as a potential biotech acquirer.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances ESMO data on lifileucel is driving attention, especially the mature frontline melanoma results with pembrolizumab and preliminary activity in sarcoma. Many traders view the melanoma response and durability findings as supportive of expansion potential, while others note the small cohorts and that the results do not establish success in the still-blinded Phase 3 TILVANCE-301 trial.

Aventus Network

Aventus is drawing attention amid a volatile rebound and speculative trading in a thinly traded, low-float token, with traders watching for a breakout as volume picks up. Bullish talk points to Aventus Clouds decentralized-compute buildout, while skeptics cite concentrated holdings, selling pressure, and the tokens recent exploit-related selloff as risks.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSpark is drawing attention after a sharp selloff amid weakness across bitcoin miners and other high-beta AI/data-center stocks, with traders pointing to macro and interest-rate pressure as well as concerns about financing costs. The community is split between dip buyers who see an oversold stock near support and bearish traders who expect further losses and continue to short it.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers extensive IDWeek pipeline presentations, including anticipated Lyme and pneumococcal vaccine data, are fueling hopes for a clinical catalyst as shares strengthen. Bulls cite momentum and options activity, while skeptics say the presentations may not deliver a meaningful surprise and point to resistance and longer-term patent-cliff concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates

Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of -50.00% and +10.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Cytokinetics (CYTK) Reports Q2 Loss, Beats Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of +7.98% and +40.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for May 27th

GYRE, FSUN and AKZOY have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2026.

Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates

Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of +16.67% and -33.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Gyre Therapeutics (NASDAQ:GYRE) Trading Up 2% - Should You Buy?

Gyre Therapeutics (NASDAQ:GYRE) Trading 2% Higher - Here's What Happened...

Gyre Therapeutics (GYRE) to Release Earnings on Tuesday

Gyre Therapeutics (NASDAQ:GYRE) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 31. (View Earnings Report at...

Zacks Research Downgrades Gyre Therapeutics (NASDAQ:GYRE) to Strong Sell

Zacks Research lowered shares of Gyre Therapeutics from a "hold" rating to a "strong sell" rating in a report on Monday...

Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.2% - Time to Sell?

Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.2% - Should You Sell...

Gyre Therapeutics (NASDAQ:GYRE) Announces Earnings Results

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) posted its earnings results on Thursday. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04). The...

Gyre Therapeutics (NASDAQ:GYRE) Downgraded by Wall Street Zen to Hold

Wall Street Zen cut Gyre Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday...

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The firm operates two distinct segments: Gyre Pharmaceuticals and Gyre. The Gyre Pharmaceuticals segment extends three major commercial drug products including ETUARY, Etorel, and Contiva as well as several product candidates in preclinical and clinical development. The Gyre segment consists of the development and commercialization of Hydronidone for the treatment of metabolic dysfunction-associated steatohepatitis associated liver fibrosis. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.

Gyre Therapeutics Inc

Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$6.08
Prev Close	$6.40
Open	$6.41
Dividend Yield	0.00%
50-Day Moving Average	$6.88
Beta	1.48
Avg. Volume	191,211.02
PE Ratio	-31.02

52-Week High	$9.14
52-Week Low	$5.44
Market Capitalization	$644.69M
EPS (Annual)	$0.0225
Price to Book	5.97
Revenue Per Employee	$186,540.80

Feed

News

Sentiment

Earnings

Fundamentals

Info

GYRE Fundamentals